WASHINGTON, Feb. 6, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is investigating claims that Indevus Pharmaceuticals Inc. (Nasdaq:IDEV) board members have breached their fiduciary duty to the corporation and its shareholders in connection with Endo Pharmaceuticals' proposed tender offer for all outstanding shares of Indevus' common stock.
The investigation is focused on allegations that the price is inadequate, that the Indevus Board of Directors has agreed to overly-restrictive deal protections, and that Indevus has failed to make sufficient disclosures to allow shareholders to make an fully informed decision in the tender offer.
If you are interested in discussing your rights as an Indevus shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.